loading
Home   |   News   |  

British American Tobacco to publish data from harm reduction study featuring Vuse e-cigarettes

British American Tobacco to publish data from harm reduction study featuring Vuse e-cigarettes

2022-07-21

British American Tobacco today released its latest scientific update, a special edition focusing on Vuse, the world's leading e-cigarette brand, and a recently completed innovative cross-sectional study.


BAT firmly believes that conducting robust, relevant and accessible scientific research is important to continue to build consumer understanding and confidence in alternative tobacco and nicotine products. Despite mounting evidence and support from public health agencies for alternative tobacco and nicotine products, many consumers are still unaware that these products are better alternatives to smoking.


The latest Science Update focuses on the Vuse cross-sectional study, which was designed to assess and provide insights into the real-world health effects of e-cigarettes.


The study compared measures of certain biomarkers of potential harm in Vuse consumers who used the product for more than six months with results from smokers, ex-smokers and never-smokers.


The BAT study will provide additional important data for the growing evidence base of Vuse's risk reduction potential, with the full set of findings due later this year.


Dr Sharon Goodall, Head of Regulatory Science at British American Tobacco, said: "Our consumers want information that is easy to understand, accessible and reliable. To achieve this, we must start with research and generate data that can be shared with regulators, public health agencies and consumers. We believe that the innovative and groundbreaking research we conduct across our product portfolio plays a key role in building understanding and confidence. That's why our regular science updates are so important.


By investing in science and innovation, British American Tobacco is accelerating a better tomorrow.


Chat Online
Chat Online
Leave Your Message inputting...
Sign in with: